A Phase 2 Study of Futibatinib in Combination with PD-1 Antibody-based Standard of Care Therapy in Patients with Solid Tumors

Brief description of study

This study wants to see if a new medicine called futibatinib, when used with pembrolizumab (a type of treatment that helps the immune system fight cancer) and chemotherapy, can help patients with a certain kind of advanced cancer in their food pipe (called esophageal cancer) and pancreatic cancer. The study has two parts: first, the study group will check if this mix of treatments has few side effects with a group of patients with esophageal cancer. Then, they'll try it on more patients with pancreatic cancer with a different chemotherapy regimen to see if it helps shrink the tumors and if the patients have positive reactions to the treatment. The study team is also checking how long this treatment keeps the cancer from growing and if it's safe for patients.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.